Salmon calcitonin combined with vitamin D3 in the treatment of hyperparathyroidism secondary to chronic renal insufficiency

Objective To explore the efficacy of salmon calcitonin combined with vitamin D3 in the treatment of chronic renal insufficiency and secondary hyperthyroidism and its effects on bone calcium metabolism. Methods A total of 40 patients with chronic renal failure who underwent hemodialysis in our blood purification center from September 2017 to December 2017 were selected for the study and were divided into treatment group (20 cases) and control group (20 cases) according to the random number table method. Patients in control group were given conventional treatment + calcitriol orally, and patients in treatment group were given subcutaneous injection of salmon calcitonin on the basis of control group. The course of treatment in both groups was 12 weeks. The clinical efficacy and clinical symptoms improvement, serum calcium, serum phosphorus and parathyroid hormone (iPTH) as well as the adverse reactions were compared between the two groups. The Kidney Disease Targeted Areas (KDTA) and Visual Analogue Pain Score (VAS) were used to evaluate the patients' quality of life and bone pain. Results The effective rate in treatment group was significantly higher than that in control group (95.00% vs 65.00%) (P 0.05). Conclusions The treatment effect of salmon calcitonin combined with vitamin D3 on chronic renal insufficiency secondary hyperthyroidism is obvious, and the clinical symptoms such as bone pain are improved obviously. It is believed that salmon calcitonin is related to the regulation of calcium, phosphorus and bone metabolism. Key words: Renal insufficiency, chronic; Hyperparathyroidism, secondary; Salmon calcitonin; Vitamin D3